

Comparison of 2004 Payment Amounts and Projected 2005 Payments (Based on ASP+6% for 2nd Quarter of 2004)

HCPCS	Name	2004 Payment for Office-Administered Drugs (Current payment rates)	Q2 2004 ASP + 6% (2005 Projected Payment)	Projected Percent Change from 2004 to 2005
J0640	Injection, leucovorin calcium, per 50 mg	\$3.00	\$1.27	-57.7%
J0780	Injection, prochlorperazine, up to 10 mg	\$3.74	\$3.20	-14.4%
J0880	Injection, darbepoetin alfa, 5 mcg	\$21.20	\$18.45	-13.0%
J1094	Injection, dexamethasone acetate, 1 mg	\$0.64	*	
J1100	Injection, dexamethasone sodium phosphate, 1 mg	\$0.10	\$0.10	0.0%
J1200	Injection, diphenhydramine HCl, up to 50 mg	\$1.43	\$0.90	-37.1%
J1260	Injection, dolasetron mesylate, 10 mg	\$13.85	*	
J1440	Injection, filgrastim (G-CSF), 300 mcg	\$158.50	\$170.51	7.6%
J1441	Injection, filgrastim (G-CSF), 480 mcg	\$267.79	\$269.23	0.5%
J1563	Injection, immune globulin, intravenous, 1 g	\$66.00	\$38.02	-42.4%
J1564	Injection, immune globulin, 10 mg	\$0.72	*	
J1626	Injection, granisetron HCl, 100 mcg	\$15.62	\$6.84	-56.2%
J1750	Injection, iron dextran, 50 mg	\$16.03	\$11.22	-30.0%
J2060	Injection, lorazepam, 2 mg	\$2.81	\$1.51	-46.3%
J2353	Injection, octreotide depot	\$77.14	\$83.38	8.1%
J2354	Injection, octreotide, non-depot	\$3.81	\$4.48	17.6%
J2355	Injection, oprelvekin	\$239.67	\$242.68	1.3%
J2405	Injection, ondansetron HCl, per 1 mg	\$5.58	\$3.80	-31.9%
J2430	Injection, pamidronate disodium, per 30 mg	\$237.88	\$57.63	-75.8%
J2505	Injection, pegfilgrastim 6 mg	\$2,507.50	\$2,277.58	-9.2%
J2550	Injection, promethazine HCl, up to 50 mg	\$2.55	\$2.17	-14.9%
J2765	Injection, metoclopramide HCl, up to 10 mg	\$1.67	\$0.47	-71.9%
J2780	Injection, ranitidine HCl, 25 mg	\$1.29	\$0.95	-26.4%
J2792	Rho(D) immune globulin h, sd	\$18.39	\$12.12	-34.1%
J2820	Injection, sargramostim (GM-CSF), 50 mcg	\$24.47	\$17.39	-28.9%
J2916	Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg	\$7.31	\$4.71	-35.6%
J3487	Injection, zoledronic acid, 1 mg	\$194.54	\$197.30	1.4%
J9000	Doxorubicin HCl, 10 mg	\$8.16	\$4.72	-42.2%
J9001	Doxorubicin HCl, all lipid formula, 10 mg	\$352.06	\$349.64	-0.7%
J9010	Alemtuzumab, 10 mg	\$523.00	\$511.50	-2.2%
J9015	Aldesleukin, per single use vial	\$657.15	\$670.39	2.0%
J9017	Arsenic trioxide, 1 mg (Trisenox)	\$32.94	\$33.15	0.6%
J9020	Asparaginase, 10,000 units	\$56.02	\$54.20	-3.2%
J9031	BCG live (intravesical), per instillation	\$143.28	\$119.89	-16.3%
J9040	Bleomycin sulfate, 15 units	\$150.61	\$68.56	-54.5%
J9045	Carboplatin, 50 mg	\$135.15	\$134.23	-0.7%
J9050	Carmustine, 100 mg	\$121.84	\$137.96	13.2%
J9060	Cisplatin, powder or solution, per 10 mg	\$13.56	\$8.01	-40.9%
J9062	Cisplatin, 50 mg	\$67.79	\$40.03	-40.9%
J9065	Injection, cladribine, per 1 mg	\$45.90	\$41.06	-10.5%
J9070	Cyclophosphamide, 100 mg	\$5.13	*	
J9080	Cyclophosphamide, 200 mg	\$9.74	*	
J9090	Cyclophosphamide, 500 mg	\$20.45	\$10.63	-48.0%
J9091	Cyclophosphamide, 1 g	\$40.92	\$20.98	-48.7%
J9092	Cyclophosphamide, 2 g	\$81.82	\$40.54	-50.5%
J9093	Cyclophosphamide, lyophilized, 100 mg	\$5.21	*	
J9094	Cyclophosphamide, lyophilized, 200 mg	\$10.41	*	
J9095	Cyclophosphamide, lyophilized, 500 mg	\$20.45	*	
J9096	Cyclophosphamide, lyophilized, 1 g	\$40.92	*	
J9097	Cyclophosphamide, lyophilized, 2 g	\$83.95	\$40.54	-51.7%
J9098	Cytarabine liposome	\$332.35	*	
J9100	Cytarabine, 100 mg	\$7.33	\$1.65	-77.5%
J9110	Cytarabine, 500 mg	\$7.65	\$4.39	-42.6%
J9120	Dactinomycin, 0.5 mg	\$12.41	\$11.97	-3.5%
J9130	Dacarbazine, 100 mg	\$10.04	*	
J9140	Dacarbazine, 200 mg	\$19.47	\$16.08	-17.4%
J9150	Daunorubicin HCl, 10 mg	\$66.42	\$26.35	-60.3%
J9151	Daunorubicin citrate, liposomal formulation, 10 mg	\$57.80	\$56.51	-2.2%
J9160	Denileukin diftitox, 300 mcg	\$1,190.85	\$1,082.86	-9.1%
J9165	Diethylstilbestrol diphosphate, 250 mg	\$12.89	*	
J9170	Docetaxel, 20 mg	\$301.40	\$290.78	-3.5%
J9178	Injection, epirubicin HCl, 2 mg	\$24.73	\$25.19	1.9%

* Medicare did not release data.

Comparison of 2004 Payment Amounts and Projected 2005 Payments (Based on ASP+6% for 2nd Quarter of 2004)

HCPCS	Name	2004 Payment for Office-Administered Drugs (Current payment rates)	Q2 2004 ASP + 6% (2005 Projected Payment)	Projected Percent Change from 2004 to 2005
J9180	Epirubicin HCl injection	\$618.26	*	
J9181	Etoposide, 10 mg	\$1.53	\$0.65	-57.5%
J9182	Etoposide, 100 mg	\$15.30	\$6.47	-57.7%
J9185	Fludarabine phosphate, 50 mg	\$318.59	\$273.54	-14.1%
J9190	Fluorouracil, 500 mg	\$1.85	\$2.26	22.2%
J9200	Floxuridine, 500 mg	\$122.40	\$72.67	-40.6%
J9201	Gemcitabine HCl, 200 mg	\$111.33	\$115.26	3.5%
J9202	Goserelin acetate implant, per 3.6 mg	\$375.99	\$216.10	-42.5%
J9206	Irinotecan, 20 mg	\$130.24	\$125.41	-3.7%
J9208	Ifosfamide, per 1 g	\$134.55	\$51.93	-61.4%
J9209	Mesna, 200 mg	\$31.45	\$16.67	-47.0%
J9211	Idarubicin HCl, 5 mg	\$375.73	\$353.15	-6.0%
J9212	Injection, interferon Alfacon-1, recombinant, 1 mcg	\$3.67	\$5.70	55.3%
J9213	Injection, interferon alfa-2a, recombinant, 3 million units	\$31.21	\$30.67	-1.7%
J9214	Interferon alfa-2b, recombinant, 1 million units	\$13.31	\$12.85	-3.5%
J9215	Interferon alfa-N3, (human leukocyte derived), 250,000 IU	\$7.03	*	
J9216	Interferon gamma-1B, 3 million units	\$187.19	\$291.08	55.5%
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	\$500.58	\$242.26	-51.6%
J9218	Leuprolide acetate, per 1 mg	\$23.26	\$11.47	-50.7%
J9219	Leuprolide acetate implant, 65 mg	\$4,831.40	\$2,197.36	-54.5%
J9230	Mechlorethamine HCl, (nitrogen mustard), 10 mg	\$10.74	\$10.41	-3.1%
J9245	Injection, melphalan HCl, 50 mg	\$375.88	\$366.71	-2.4%
J9250	Methotrexate sodium, 5 mg	\$0.35	\$0.22	-37.1%
J9260	Methotrexate sodium, 50 mg	\$4.25	\$2.21	-48.0%
J9263	Oxaliplatin	\$8.45	\$8.16	-3.4%
J9265	Paclitaxel, 30 mg	\$138.28	\$17.84	-87.1%
J9266	Pegaspargase, per single dose vial	\$1,277.13	*	
J9268	Pentostatin, per 10 mg	\$1,644.27	\$1,853.45	12.7%
J9270	Plicamycin, 2.5 mg	\$83.93	*	
J9280	Mitomycin, 5 mg	\$57.12	\$23.63	-58.6%
J9290	Mitomycin, 20 mg	\$185.64	\$66.35	-64.3%
J9291	Mitomycin, 40 mg	\$255.00	\$128.60	-49.6%
J9293	Injection, mitoxantrone HCl, per 5 mg	\$321.52	\$314.53	-2.2%
J9300	Gemtuzumab ozogamicin, 5mg	\$1,953.94	\$2,196.48	12.4%
J9310	Rituximab, 100 mg	\$438.38	\$438.38	0.0%
J9320	Streptozocin, 1 g	\$126.58	\$178.72	41.2%
J9340	Thiotepa, 15 mg	\$83.73	\$47.90	-42.8%
J9350	Topotecan, 4 mg	\$706.17	\$736.13	4.2%
J9355	Trastuzumab, 10 mg	\$52.01	\$52.04	0.1%
J9357	Valrubicin, intravesical, 200 mg	\$471.24	*	
J9360	Vinblastine sulfate, 1 mg	\$2.81	\$0.61	-78.3%
J9370	Vincristine sulfate, 1 mg	\$30.40	\$5.00	-83.6%
J9375	Vincristine sulfate, 2 mg	\$60.81	\$10.00	-83.6%
J9380	Vincristine sulfate, 5 mg	\$152.02	\$24.99	-83.6%
J9390	Vinorelbine tartrate, per 10 mg	\$76.19	\$60.46	-20.6%
J9395	Injection, Fulvestrant	\$81.57	\$79.11	-3.0%
J9600	Porfimer sodium, 75 mg	\$2,329.60	\$2,283.91	-2.0%
Q0136	Injection, epoetin alpha, (for non ESRD use), per 1,000 units	\$11.62	\$10.34	-11.0%
Q3025	IM injection, interferon beta 1-a	\$80.22	\$85.79	6.9%
	Denileukin diftitox (Ontak) 150 mcg	\$595.42	*	

* Medicare did not release data.